In a recent article in the Journal of the European Optical Society-Rapid Publications, researchers use devices based on a diffractive optical element to analyze the surface of pharmaceutical tablets. Using antimalarial drugs as a test, these simple and affordable devices can help detect counterfeit tablets and serve as a quality assurance tool for pharmaceutical production sites.
Monthly Archives: July 2017
For systematic reviews to be considered a gold standard, it is vital that they are methodologically sound and well reported. To ensure this, there are a plethora of tools available to researchers; knowing which to use, however, isn’t always easy. In this blog Kusala Pussegoda, author of a paper published today in Systematic Reviews discusses which tools and guidelines are most appropriate in different contexts.
With publication bias being a huge issue in medical literature, policies that set out to mitigate bias, such as the 2007 FDA Amendment Act, are certainly welcome. But just how effective has this policy been in improving the transparency of trial publication? Here to tell us, are authors of a new study published today in Trials.
A new paper published today in Trials looks at how to prepare anonymized patient level data from a clinical trial to make available to other external researchers. By working through the process to anonymize data from two publicly funded clinical trials, we have estimated the time it takes to do this and how much this would cost.1
Height, obesity and prostate cancer risk: the importance of looking at different tumour characteristics
Taller men and men with more body fat are both at an increased risk of high grade prostate cancer and death from prostate cancer, finds a new study published in BMC Medicine which analyzed data from the EPIC cohort. In this blog author of the study, Dr Aurora Perez-Cornago, tells us about the findings and the importance of differentiating between high grade and advanced stage tumors
This June saw the fifth annual Cancer Immunotherapy Month uniting patients, caregivers, advocacy organizations, health care professionals and industry partners who share the common goal of raising awareness of the lifesaving potential of cancer immunotherapies. Immunotherapy, often referred to as biotherapy, is exactly what the name infers — treatment that uses parts of the immune system to fight diseases such as cancer. Cancer-specific immunotherapy, also known as immuno-oncology, is one of the largest areas of immunotherapy research.
The incidence of thyroid cancer has been rising steadily in the United States and around the world, but the reason does not seem to be an inherent rise in thyroid cancer incidence, but rather the increased detection of thyroid cancer. Here to tell us about detecting indolent thyroid cancer and the pros and cons of active surveillance is Dr. Lewis D. Hahn and Dr. Terry S. Desser, authors of a study published in Cancers of the Head & Neck.
Chief Medical Officer’s fifth annual report (advocacy volume) on genomics highlights the potential for pathogen genomics in patient diagnosis and infection control
The Chief Medical Officer’s (CMO) fifth annual report (advocacy volume) on genomics was published earlier this week. This sets out the latest evidence-based understanding of genomics in clinical practice in a series of chapters written by leading experts in their field, together with recommendations by the CMO that will drive this innovation closer and more rapidly towards patient care and benefit.